New developments in gonadotrophin pharmacology.
This article reviews the past, present, and future of gonadotrophin therapy, including purification of gonadotrophins from animal or human urine sources and production of gonadotrophins through recombinant technology. With the advent of recombinant DNA methodologies combined with site-directed mutagenesis, a variety of structural modifications becomes possible.
Gordon
Keith
K
Reproductive Medicine, Organon Pharmaceuticals Inc, 56 Livingston Avenue - 4th Floor, Roseland, NJ 07068, USA.
D000818:Animals; D006063:Chorionic Gonadotropin / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology; D005260:Female; D005640:Follicle Stimulating Hormone / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology; D014644:Genetic Variation; D006062:Gonadotropins / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology*; D006801:Humans; D007986:Luteinizing Hormone / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology; D008958:Models, Molecular; D021122:Protein Subunits; D011994:Recombinant Proteins / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology
D006063:Chorionic Gonadotropin; D006062:Gonadotropins; D021122:Protein Subunits; D011994:Recombinant Proteins; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone